Navigation Links
NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
Date:2/27/2008

forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements regarding the timing of potential commercial launch of NGX- 4010; the timing of filings for regulatory approval and the indications potentially being sought in such filings; the indications for which NGX-4010 may be approved for use; the potential markets for NGX-4010; the potential efficacy and benefits of NGX-4010; the potential use of data from the recently completed clinical trial in HIV-DSP to support efficacy; and NeurogesX' plans to commercialize NGX-4010, including with respect to sales force plans and plans to enter into commercial partnerships. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, data from the recently completed clinical trial in HIV-DSP may have an effect on the potential regulatory approval of NGX-4010, and approved indications of such approval, if any; positive results in certain clinical trials may not be sufficient to obtain FDA or European regulatory approval; subsequent analysis of data from NeurogesX' past clinical trials may cause the results to be viewed less favorably as compared to the initial analysis of such results; past results of clinical trials may not be indicative of future clinical trials results; NGX-4010 may have unexpected adverse side effects or inadequate therapeutic efficacy; physician or patient reluctance to use NGX- 4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies and changing standards of care; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; NeurogesX' ability to obtain additional financing; NeurogesX' ability to obtain and maintain futur
'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
4. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
5. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
6. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
7. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
8. amfAR Announces Funding for HIV Services and Research Aimed at Men Who Have Sex With Men in Developing Countries
9. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
10. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
11. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... -- Organovo Holdings, Inc. (NYSE MKT: ONVO) today announced preliminary ... year ended March 31, 2015. Based on ... March 31, 2015, Organovo estimates: , Total ... and approximately $571 thousand for the fiscal year , ... and fiscal year ended March 31, 2015 of approximately ...
(Date:4/21/2015)... --Algae International Group, Inc. ( ALGA ), through its ... exceptional Hempster T-Shirt sales following yesterday,s online sales launch. ... introduced four t-shirt designs specific to the ,Hempster Clothing, ... the online sales of these first four t-shirts over ... to the  Marijuana Policy Project  (MPP), an organization dedicated ...
(Date:4/21/2015)... April 21, 2015 Global cap ... World demand for caps and closures will exceed $55 billion ... exceed two trillion annually. Beverages will continue to account for ... and a number of smaller markets are expected to register ... Although the most developed markets -- the US, ...
Breaking Medicine Technology:Organovo Holdings, Inc. Pre-Announces Preliminary Fiscal 2015 Fourth Quarter And Year End Financial Information 2Organovo Holdings, Inc. Pre-Announces Preliminary Fiscal 2015 Fourth Quarter And Year End Financial Information 3Organovo Holdings, Inc. Pre-Announces Preliminary Fiscal 2015 Fourth Quarter And Year End Financial Information 4American Seed & Oil Company 420 Hempster T-Shirt Sales Soar; Online Sales Launched Yesterday with Start of 420 Week; Over 2000 Shirts Sold So Far 2World Caps & Closures Market 2World Caps & Closures Market 3
(Date:4/21/2015)... Displays & Exhibits, Inc. a division of Absolute ... building industry, announced a management change of the retail ... in Tustin, California.“It is very important to have a ... in quality as offered by overseas trade show accessories ... Adduru is the new manager of Displays & Exhibits ...
(Date:4/21/2015)... Henry Mayo Newhall Hospital, located in California’s ... to automatically send continuation of care documents (CCDs). When ... communication with clinics and other ambulatory practices, they selected ... , “Provider Alert will enable the physician offices ... need to provide continuing care in real time,” said ...
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 22, 2015 ... Pipeline Review, H1 2015” provides comparative analysis ... The report strengthens R&D pipelines by identifying ... and best-in-class products. Complete report with TOC ... , The report also reviews key players ...
(Date:4/21/2015)... 21, 2015 The report ... comparative analysis on the therapeutic development for ... identifying new targets and MOAs to produce ... TOC is available @ http://www.rnrmarketresearch.com/sinusitis-pipeline-review-h1-2015-market-report.html ... players involved in the therapeutic development for ...
(Date:4/21/2015)... Information is the best weapon in the fight for your ... their families with knowledge about living with cancer in his ... Answer" and new website . , In the book, ... diagnosis through treatment and even death. The goal, he says, ... home and in the examination room. , “Cancer patients and ...
Breaking Medicine News(10 mins):Health News:Displays & Exhibits Reveals Tustin, California Showroom Under New Management 2Health News:Henry Mayo Newhall Hospital to Improve Ambulatory Information Sharing with Summit Healthcare's Summit Provider Alert 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2
... The following is being issued by Cheryl ... 721 will streamline the health care process for ... long waits and associated, unnecessary costs because they ... treatment."Currently, patients seeking rehabilitation for functional impairments due ...
... experts say, , , THURSDAY, March 5 (HealthDay News) -- Men ... life span by more than two years, Swedish researchers say. ... beneficial effect on length of life as quitting smoking in ... exercise, the researchers said. But Dr. Karl Michaëlsson, a senior ...
... Group, Inc. (OTC Bulletin Board: POLGA ; OTC ... marketer of engineered materials, announced today it will release ... of the market on Wednesday, March 18, 2009. Company ... slides, starting at 10:00 a.m. EDT on Thursday, March ...
... March 5 Despite dermatologists, continual efforts, ... harmful effects of excessive sun exposure and regular use ... to reduce the risk of developing skin cancer. But ... may help encourage them to apply sunscreen regularly via ...
... BRIARCLIFF MANOR, N.Y., March 5 SETO Holdings, Inc. (Pink ... under which it agreed in principle (1) to issue shares ... stock of Advanced Hearing Centers, Inc. ("AHC"), a Maryland corporation ... locations in Maryland and one in Virginia, and (2) to ...
... of infection, study says , , THURSDAY, March 5 (HealthDay News) ... existing vaccines so that they can protect people during a ... ,killer T-cell, is the hit-man of the immune system. It ... body, helping rid us of infections," the study,s lead author, ...
Cached Medicine News:Health News:Men Who Get Active in Midlife Live Longer 2Health News:Men Who Get Active in Midlife Live Longer 3Health News:Polymer Group, Inc. Announces Fourth Quarter and Year-End 2008 Earnings Conference Call 2Health News:New Study Finds Text-Messaging Reminders Effective in Improving Adherence to Sunscreen Use 2Health News:New Study Finds Text-Messaging Reminders Effective in Improving Adherence to Sunscreen Use 3Health News:New Study Finds Text-Messaging Reminders Effective in Improving Adherence to Sunscreen Use 4Health News:SETO Holdings, Inc. Signs Letter of Intent to Dispose of all its Existing Businesses and Acquire Advanced Hearing Centers, Inc.; New Management to be Installed. 2
Used for the introduction of catheters, balloons and other vascular devices....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used for contralateral access to the iliac artery for interventional procedures after initial wire guide positioning has been established....
Used to introduce balloon, electrode, closed or non-tapered end and other catheters....
Medicine Products: